Sign In
Buy SHIEF
$0.0800
+0 (+0%)
At Close: Jun 02, 2026
Shield Therapeutics plc (SHIEF) Q1 2026 Sales/Trading Call Transcript
03:51pm, Tuesday, 05'th May 2026
Shield Therapeutics plc (SHIEF) Q1 2026 Sales/Trading Call Transcript
Shield Therapeutics drops as CFO exits and Medicaid concerns weigh
05:06am, Friday, 01'st May 2026
Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) fell 12% to 7.71p after the group reported first-quarter revenue growth and positive earnings but...
Shield Therapeutics drops as CFO exits and Medicaid concerns weigh
04:16am, Friday, 01'st May 2026
Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) fell 12% to 7.71p after the group reported first-quarter revenue growth and positive earnings but flagged potential headwinds in the US market
Shield shares jump after FDA extends Accrufer exclusivity
09:51am, Monday, 09'th Feb 2026
Broker Cavendish says additional US protection strengthens long-term outlook and reiterates buy rating. Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) jumped as much 11% earlier in the sess
Shield Therapeutics plc (SHIEF) Q4 2025 Sales/Trading Call Transcript
03:24am, Friday, 23'rd Jan 2026
Shield Therapeutics plc (SHIEF) Q4 2025 Sales/Trading Call Transcript
Shield Therapeutics shares positive efficacy data for iron deficiency treatment
03:17am, Wednesday, 01'st Oct 2025
Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) has announced positive results from its Phase 3 pediatric FORTIS trial of ferric maltol (ACCRUFeR). The trial tested children and adolescents with iron
Shield Therapeutics lifted as US FDA extends Accufer approval
03:31am, Thursday, 04'th Sep 2025
Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) shares climbed in Thursday's early trade after it announced that the US Food and Drug Administration has accepted its submission to extend the label fo
Shield Therapeutics shares surge 21% as ACCRUFeR revenues double
07:48am, Wednesday, 23'rd Jul 2025
Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) saw its share price rise 21% following a strong second-quarter trading update. The company reported that net revenues from its iron deficiency treatment,
Shield Therapeutics rises on Japan licensing deal for iron deficiency drug
06:26am, Tuesday, 22'nd Apr 2025
Shares in Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) rose as much as 6% on Tuesday morning after the company announced a licensing agreement that will see its iron deficiency treatment ACCRUFeR b
Shield Therapeutics edges closer to profitability as US sales surge
05:14am, Tuesday, 25'th Feb 2025
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) is gaining momentum. The company, known for its oral iron supplement ACCRUFeR, has reported a strong end to 2024, with US sales driving record revenues f
Shield Therapeutics shares rise on the back of $10m fundraiser
11:49am, Friday, 06'th Dec 2024
Shares of Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) rose in afternoon trading after the company announced a $10 million fundraising commitment from its largest investor, AOP Health International.
Shield Therapeutics unveils premium fundraiser
07:54am, Friday, 06'th Dec 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), a specialist in iron deficiency treatments, said its largest investor, AOP Health International, is backing a $10 million fundraiser. It will subscribe
Shield Therapeutics ‘on track for 2024' - analyst
09:22am, Thursday, 21'st Nov 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s proposed $10 million equity agreement with AOP Health International Management “should provide some much-needed breathing room” for the AIM-listed
Shield Therapeutics up 27% after impromptu trading update
04:30am, Thursday, 21'st Nov 2024
Shares of Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) surged 27% in early trading after strong October sales of its iron deficiency drug ACCRUFeR, driven by an increase in net selling price to over
Shield Therapeutics on course in China as sales growth continues
02:47am, Thursday, 21'st Nov 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)) has reported strong sales of iron deficiency drug ACCRUFeR in October, bolstered by an increase in the net selling price to over $225 per prescription,
